Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Canine Atopic Dermatitis Market Evolve in Terms of Growth and Size by 2029?

In the last few years, the market size for canine atopic dermatitis has seen rapid expansion. It is forecasted to rise from $2.49 billion in 2024 to $2.76 billion in 2025, with a compound annual growth rate (CAGR) of 10.6%. The growth observed during the historic period can be traced back to factors like a surge in pet ownership, heightened consciousness about pet health, an increase in the prevalence of allergic conditions in dogs, rising expenditure in veterinary healthcare, and enhanced availability of pet insurance.

The market size for canine atopic dermatitis is forecasted to witness substantial growth in the upcoming years, ballooning to $4.09 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 10.3%. This growth in the projected period can be assigned to the rise in the use of telemedicine in pet care, an increased demand for individualized pet therapies, surging investments in veterinary R&D, an increase in the trend of pet humanization, and a growing application of artificial intelligence in veterinary diagnostic procedures. Anticipated trends within this period include the advancement of monoclonal antibody therapies, integration of AI in veterinary diagnostics, the inclusion of telemedicine for dermatology, the use of wearable devices for tracking symptoms, sophisticated allergen-specific immunotherapies, and the emergence of mobile applications for treatment tracking.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25717&type=smp

What factors are expected to fuel Canine Atopic Dermatitis market growth in the coming years?

An upward trend in skin allergy cases among dogs is predicted to stimulate the expansion of the canine atopic dermatitis market. Dog skin allergies are abnormal immunological reactions to allergens like pollen, food, or insect bites, leading to symptoms such as itchiness, erythema, and dermal irritation. This upsurge in dog skin allergies can be partially linked to heightened exposure to environmental pollutants and allergens, known to catalyse intense immunological reactions and dermal irritation. The treatment of atopic dermatitis in dogs helps handle dermal allergies in them by decreasing inflammation and itchiness and inhibiting secondary infections, thus improving their comfort and dermal health. For example, as per the National Institutes of Health (NIH), a US government body, in January 2024, a total of 7,915 dog parents (28.7%) confirmed their dogs suffered from dermal conditions. The reporting frequency of dermal problems spiked consistently with growing age, beginning at 7% in puppies to 37% in aged dogs. Consequently, the surge in dog skin allergy cases is pushing the growth of the canine atopic dermatitis market. Escalating pet ownership is also projected to boost the expansion of the canine atopic dermatitis market. Pet ownership implies owning and taking care of a domesticated animal like a dog, cat, bird, or a different companion animal, as a house member. The escalating pet ownership is due to the humanising of pets, animals being treated as family members, pushing demand for companionship and emotional support. Treating atopic dermatitis in dogs advantageously eases chronic itchiness and inflammation, betters dermal health, and amplifies their overall comfort and life quality. As per the American Pet Products Association (APPA), a US trade association that manufactures pet products, 94 million US households (71%) possess a pet in 2025, marking an increase from 86.9 million (66%) pet owning US households in 2023-2024. Consequently, escalating pet ownership is fuelling the expansion of the canine atopic dermatitis market.

What Are The Key Findings From The Segmentation Analysis Of The Canine Atopic Dermatitis Market?

The canine atopic dermatitis market covered in this report is segmented –

1) By Product: Glucocorticoids, Antihistamines, Immunosuppressants, Monoclonal Antibodies (mAbs), Other Products

2) By Dog Breed: German Shepherd, Terriers, Retrievers, Other Dog Breeds

3) By Indication: Ectoparasites, Food Allergy, Allergic Skin Infections, Other Indications

4) By Route Of Administration: Oral, Topical, Injectable

5) By Distribution Channel: Veterinary Clinics, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone

2) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine

3) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil

4) By Monoclonal Antibodies: Lokivetmab, Investigational Monoclonal Antibodies

5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics

Which Trends Are Expected To Shape The Future Of The Canine Atopic Dermatitis Market?

The dominant players in the canine atopic dermatitis market are working towards obtaining regulatory approvals to amplify their therapies’ global access and usage. These regulatory approvals are the official authorizations given by governmental health agencies. They permit companies to distribute and sell their medical products after these products have successfully passed comprehensive safety, efficacy, and quality tests. For example, Elanco Animal Health Inc., an American animal health pharmaceutical company, obtained US FDA approval for Zenrelia in September 2024. Zenrelia is a daily oral JAK inhibitor for dogs suffering from allergic and atopic dermatitis.Zenrelia’s approval marks a crucial step forward in the treatment of dogs with chronic, acute, or seasonal itch and inflammation with a single daily tablet. It operates by targeting and blocking the pathways responsible for allergic itches, effectively disrupting the itch-scratch cycle. Observational improvements can be seen from the first dose of Zenrelia, and it minimizes the risk of rebound itch, a common difficulty in numerous dogs treated with rival JAK inhibitors.

What Are The Most Active Companies In The Canine Atopic Dermatitis Market Today?

Major companies operating in the canine atopic dermatitis market are Merck & Co. Inc., Zoetis Inc., Hill’s Pet Nutrition Inc., IDEXX Laboratories Inc., Royal Canin SAS, Ceva Santé Animale S.A., Boragen, Virbac S.A., Elanco Animal Health Inc., Dechra Pharmaceuticals PLC, Antech Diagnostics Inc., Vetoquinol S.A., Heska Corporation, Bioiberica S.A.U., Bimeda Animal Health Limited, Animal Dermatology Group Inc., Kindred Biosciences Inc., Bioceltix S.A., Nextmune AB, OKAVA Pharmaceuticals Inc

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/canine-atopic-dermatitis-global-market-report

Which Regional Markets Are Attracting The Most Investment In Canine Atopic Dermatitis?

North America was the largest region in the canine atopic dermatitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the canine atopic dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25717&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model